The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene therapy designed to restore a neurosensory function to normal levels.
In a new study published in the journal Science, researchers from the Royal Botanic Gardens, Kew, ZSL (Zoological Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results